邦基科技(603151.SH):雲南項目設計產能是18萬噸,遼寧項目設計產能是12萬噸
格隆匯4月20日丨有投資者在投資者互動平台向邦基科技(603151.SH)提問,“請問董祕兩個問題:一是公司募投項目雲南和遼寧項目已經投產,請問是具體何時投產?二是公司招股書上説明募投項目的雲南和遼寧項目合計是否是30萬噸產能?請問何時能滿產?”
邦基科技回覆稱,雲南項目設計產能是18萬噸,遼寧項目設計產能是12萬噸;公司採用“以銷定產”的生產模式,新建成項目產能隨着銷售市場的開拓正逐步釋放,目前處於產能爬坡階段,公司將加大市場拓展投入力度、提高市場佔有率,儘早達到滿產狀態,創造更好的經濟效益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.